Jefferies reiterated its Buy rating and $18 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) Monday following positive management meetings.

This article: 136 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE